Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film
UPPSALA, 2 December, 2021. Klaria Pharma AB (Nasdaq Stockholm: KLAR) announces today that is has received approval from the regulatory authorities in the United Kingdom (MHRA) to carry out a clinical Phase 1 study with Naloxone Alginate Film, a new treatment of opioid overdose. With a more patient friendly formulation that is being specifically developed to meet the needs of patients and caregivers today, Naloxone Alginate Film has the potential to be significantly superior to all Naloxone nasal sprays currently in use.Naloxone Alginate Film is addressing a market with significant unmet